1. Home
  2. ONEW vs ENGN Comparison

ONEW vs ENGN Comparison

Compare ONEW & ENGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo OneWater Marine Inc.

ONEW

OneWater Marine Inc.

HOLD

Current Price

$9.85

Market Cap

158.8M

ML Signal

HOLD

Logo enGene Holdings Inc.

ENGN

enGene Holdings Inc.

HOLD

Current Price

$2.00

Market Cap

117.2M

Sector

N/A

ML Signal

HOLD

Company Overview

Basic Information
Metric
ONEW
ENGN
Founded
2014
1999
Country
United States
Canada
Employees
N/A
N/A
Industry
Auto & Home Supply Stores
Sector
Consumer Discretionary
Exchange
Nasdaq
Nasdaq
Market Cap
158.8M
117.2M
IPO Year
2019
2023

Fundamental Metrics

Financial Performance
Metric
ONEW
ENGN
Price
$9.85
$2.00
Analyst Decision
Strong Buy
Buy
Analyst Count
4
6
Target Price
$16.50
$21.08
AVG Volume (30 Days)
87.5K
676.6K
Earning Date
04-30-2026
06-11-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
56.85
EPS
2.77
N/A
Revenue
$1,872,334,000.00
N/A
Revenue This Year
$0.30
N/A
Revenue Next Year
$3.14
N/A
P/E Ratio
$3.70
N/A
Revenue Growth
5.62
N/A
52 Week Low
$8.12
$1.40
52 Week High
$17.35
$12.25

Technical Indicators

Market Signals
Indicator
ONEW
ENGN
Relative Strength Index (RSI) N/A N/A
Support Level N/A N/A
Resistance Level N/A N/A
Average True Range (ATR) 0.00 0.00
MACD 0.00 0.00
Stochastic Oscillator 0.00 0.00

Price Performance

Historical Comparison
ONEW
ENGN

About ONEW OneWater Marine Inc.

OneWater Marine Inc is a recreational marine retailer in the United States. The company operates in two segments: Dealership and Distribution. The Dealership segment is involved in selling new and pre-owned boats. It also arranges financing and insurance products, provides repairs and maintenance services, offers marine-related parts and accessories, and supplies slip and storage accommodations at certain locations. The Distribution segment focuses on the manufacturing, assembly, and distribution of marine-related products. These products are supplied to distributors, box retailers, and online retailers through a network of warehouses and distribution centers. The company generates the majority of its revenue from the Dealership segment.

About ENGN enGene Holdings Inc.

enGene Therapeutics Inc is a clinical-stage biotechnology company mainstreaming gene therapy through the delivery of therapeutics to mucosal tissues and other organs, to create new ways to address diseases with high clinical needs. Its pioneering program is detalimogene voraplasmid (also known as detalimogene) for patients with Non-Muscle Invasive Bladder Cancer (NMIBC), a disease with a high clinical burden. Detalimogene is being evaluated in the ongoing multi-cohort LEGEND Phase 2 trial, which includes a pivotal cohort studying detalimogene in high-risk, Bacillus Calmette-Guerin (BCG)-unresponsive patients with carcinoma in situ (CIS) with or without concomitant papillary disease. It is developed using enGene's proprietary Dually Derivatized Oligochitosan (DDX) platform.

Share on Social Networks: